Analysis of Drug Medical Insurance Access Pricing Based on the Perspective of Binary Equilibrium

Abstract

Objective To study the influencing factors in the process of national medical insurance negotiation and drug pricing from the dualistic equilibrium perspective, and to provide reference for the harmonious management of drug pricing in China. Methods Through the literature analysis and policy review, the pricing subject, pricing basis and price control system in the pricing process of medical-accessed medicines were analyzed from the perspective of binary equilibrium and harmonious management. Results and Conclusion It is found that four balances in the drug pricing process, two balances in pricing basis and three balances in price control system need to be considered, respectively. Drug pricing is the key content of national medical insurance access, which is also the hotspot of the policy in the pharmaceutical fields in recent years. Drug pricing not only reflects the value of drugs, but also reflects a lot of top-level designs of binary equilibriums in medical insurance policy. While the rational design of drug pricing requires the joint efforts of the government, pharmaceutical companies and relevant experts to comprehensively consider many equilibriums, so as to improve the relevant systems.

Keywords

medical insurance access / drug pricing / binary equilibrium

References

[1] National Healthcare Security Administration. Opinions on Managing the Current Drug Price[EB/OL]. (2019-11-26)[2023-11-04]. https://www.gov.cn/zhengce/zhengceku/2019-12/08/content_5562279.htm.

[2] National Healthcare Security Administration. Work Plan for Adjustment of the National Basic Medical Insurance Work Injury Insurance and Maternity Insurance Drug Catalog in 2023[EB/OL]. (2023-06-29)[2023-11-04]. http://www.nhsa.gov.cn/art/2023/6/29/art_109_10921.html.

[3] Neri M, Towse A, Garau M. Multi-indication pricing (MIP): Solutions and steps to move forward[R]. London: Office of Health Economics, 2018.

[4] Bao Shiyi, Yang Yi, Ming Jian, et al. International experience and enlightenment of value-based pricing policies[J]. Chinese Health Economics, 2022, 41 (4): 1-4.

[5] National Healthcare Security Administration. Application Guidelines for Adjustment of the National Basic Medical Insurance Work Injury Insurance and Maternity Insurance Drug Catalog in 2023[EB/OL]. (2023-06-29)[2023-11-04]. http://www.nhsa.gov.cn/art/2023/6/29/art_109_10921.html.

[6] Tan Qingli, Guo Runyi, Sun Huilin, et al. Synergy of centralized drug volume-based purchasing and medical insurance negotiation policy[J]. China Pharmacy, 2021, 32 (15): 1793-1799.

[7] Zhao Jing. Research on pharmacoeconomic evaluation in drug price management[J]. Price: Theory & Practice, 2022 (3): 59-62.

[8] Wu Lin, Chen Yongfa, Liu Tingting. The practice of British patent drug NHS access management and its enlightenment to China[J]. Chinese Journal of Pharmaceuticals, 2017, 48 (10): 1527-1533.

[9] Yan Jianzhou, Li Dashuang, Ren Xiaoyue, et al. International experience and enlightenment of innovative drug medical insurance access differentiated management[J]. China Health Insurance, 2023 (1): 5-11.

[10] Yang Zirui, Tao Tiantian, Jiang Rong, et al. Study on Australian deeds of agreement and its enlightenment to China[J]. Chinese Health Economics, 2020, 39 (6): 93-96.

[11] Ju Qiang. Entering harmonious management - A review of dualistic relative balance management philosophy (part 1)[J]. Business Research, 2007 (1): 49-55.

[12] Shen Jiawen. Development strategies and policy considerations for innovative biological drugs in China[J]. China Economic & Trade Herald, 2023 (3): 64-67.

[13] Wu Lin. Research on the construction of government leadership in the management of patented drug and medical insurance access negotiation[J]. Chinese Journal of Health Policy, 2020, 13 (2): 10-18.

[14] Li Saisai, Xu Wei, Wang Yuhao, et al. Research on access to the list of innovative medicines[J]. Health Economics Research, 2019, 36 (10): 40-43.

[15] Jia Qian, Zhuang Qian. Research on the impact of supplementary medical insurance on the utilization of medical services for middle-aged and elderly people[J]. Science Technology and Industry, 2023, 23 (14): 48-53.

[16] Zheng Qi, Lin Chunsheng, Guan Xi, et al. The research review on full life cycle management of medical insurance for drug under the background of comprehensive health[J]. Soft Science of Health, 2022, 36 (5): 17-22.

[17] Liu Wanlei, Huang Zhe. Two-sided cogitation about access mechanism to medical insurance list from meet demand and promotion R&D of innovative medicine[J]. China Health Standard Management, 2023, 14 (10): 58-64.